LV15035A - Sequences of cdna of recombinant chimeric polypeptide having type two melanocortin receptor (mc2r) and melanocortin receptor accessory protein (mrap) and a use of them for testing active molecules and for therapeutic purposes - Google Patents

Sequences of cdna of recombinant chimeric polypeptide having type two melanocortin receptor (mc2r) and melanocortin receptor accessory protein (mrap) and a use of them for testing active molecules and for therapeutic purposes

Info

Publication number
LV15035A
LV15035A LVP-13-229A LV130229A LV15035A LV 15035 A LV15035 A LV 15035A LV 130229 A LV130229 A LV 130229A LV 15035 A LV15035 A LV 15035A
Authority
LV
Latvia
Prior art keywords
melanocortin receptor
mc2r
mrap
cdna
sequences
Prior art date
Application number
LVP-13-229A
Other languages
Latvian (lv)
Other versions
LV15035B (en
Inventor
Dāvids Fridmanis
Jānis Kloviņš
Ilona Mandrika
Ramona PETROVSKA
Ance Roga
Original Assignee
Latvijas Biomedicīnas Pētījumu Un Studiju Centrs, App
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvijas Biomedicīnas Pētījumu Un Studiju Centrs, App filed Critical Latvijas Biomedicīnas Pētījumu Un Studiju Centrs, App
Priority to LVP-13-229A priority Critical patent/LV15035B/en
Publication of LV15035A publication Critical patent/LV15035A/en
Publication of LV15035B publication Critical patent/LV15035B/en

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

Invention relates to the field of molecular biology and pharmacological testing, specifically to fusion of human melanocortin receptor type two (MC2R) and human melanocortin receptor accessory protein (MRAP) into single polypeptide useful in screening for novel MC2R ligands.
LVP-13-229A 2013-12-27 2013-12-27 Sequences of cdna of recombinant chimeric polypeptide having type two melanocortin receptor (mc2r) and melanocortin receptor accessory protein (mrap) and a use of them for testing active molecules and for therapeutic purposes LV15035B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
LVP-13-229A LV15035B (en) 2013-12-27 2013-12-27 Sequences of cdna of recombinant chimeric polypeptide having type two melanocortin receptor (mc2r) and melanocortin receptor accessory protein (mrap) and a use of them for testing active molecules and for therapeutic purposes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-13-229A LV15035B (en) 2013-12-27 2013-12-27 Sequences of cdna of recombinant chimeric polypeptide having type two melanocortin receptor (mc2r) and melanocortin receptor accessory protein (mrap) and a use of them for testing active molecules and for therapeutic purposes

Publications (2)

Publication Number Publication Date
LV15035A true LV15035A (en) 2015-07-20
LV15035B LV15035B (en) 2015-12-20

Family

ID=53540002

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-13-229A LV15035B (en) 2013-12-27 2013-12-27 Sequences of cdna of recombinant chimeric polypeptide having type two melanocortin receptor (mc2r) and melanocortin receptor accessory protein (mrap) and a use of them for testing active molecules and for therapeutic purposes

Country Status (1)

Country Link
LV (1) LV15035B (en)

Also Published As

Publication number Publication date
LV15035B (en) 2015-12-20

Similar Documents

Publication Publication Date Title
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2018013981A (en) Improved peptide pharmaceuticals for insulin resistance.
AU2019201173B2 (en) Novel polypeptides
MX2021006017A (en) Methods and compositions for treatment of disorders with follistatin polypeptides.
MX344219B (en) Improved peptide pharmaceuticals for insulin resistance.
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MY180831A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
MX340498B (en) Heterodimerized polypeptide.
MX2016011580A (en) Serum albumin-binding fibronectin type iii domains.
EA201591700A1 (en) HYBRID PROTEINS APELINA AND THEIR APPLICATION
WO2014026054A3 (en) CD20 scFv-ELPs METHODS AND THERAPEUTICS
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
NZ603570A (en) Biological materials related to her3
WO2017053619A8 (en) Glypican-3binding fibronectin based scafflold molecules
MX2015006548A (en) Binding proteins comprising at least two repeat domains against her2.
EA201500172A1 (en) MODIFIED POLYPEPTIDES OF THE FACTOR X AND THEIR APPLICATION
CY1117214T1 (en) COMPOSITION FOR CONTROLLED OVENTION STUDY
MX2013015324A (en) Wap domain fusion polypeptides and methods of use thereof.
TR201905619T4 (en) Peptide carrier fusion proteins as allergy vaccines.
MX2016015594A (en) Improved peptide pharmaceuticals for insulin resistance.
PH12014501363A1 (en) Anticancer fusion protein
MX2021012047A (en) Serpin fusion polypeptides and methods of use thereof.
MX366178B (en) Human btnl3 proteins, nucleic acids, and antibodies and uses thereof.
IL276616A (en) Dosing for treatment with il-22 fc fusion proteins
LV15035A (en) Sequences of cdna of recombinant chimeric polypeptide having type two melanocortin receptor (mc2r) and melanocortin receptor accessory protein (mrap) and a use of them for testing active molecules and for therapeutic purposes